Extensive entrepreneurial experience in adoption and commercialization of emerging materials and nanotechnology.

At one time worked with Chevron team that built and grew Molecular Diamond Technologies, a new nanomaterials focused business unit. While with Hitachi worked in the areas of emerging electronics, energy and life sciences applications. At MIT was part of team that discovered a fundamental particle called the top quark at the Fermi National Accelerator Laboratory in 1995.

Co-founder and Steering Committee Chair of MIT Stanford UC Berkeley Nanotechnology Forum, and worked with PCAST (Presidential Council of Advisors on Science and Technology) on issues related to energy.

Founded in 2004, a full-service provider to pharmaceutical, medical device, dietary Supplement, veterinary and cosmetic industries. 25 years experience in FDARegulated industries. Innovator of client product concept, quality control, training,IT solutions, sales and marketing.

Scientist, executive, and entrepreneur, with over 25 years experience in biotechnology. Co-Founder of HemoBioTech, developing potentially the first viable substitute for human blood. Also co-Founded Biogress (a biotech service company) and Cytoclonal Pharmaceutics, raising some $65 million, then implementing a licensing agreement with Bristol-Myers Squibb and acquiring Nobel Prize technology for computer based drug design.

The author of more than 50 scientific communications. Also served as Editor of the CRC Press Publication "Recombinant DNA Products: Insulin, Interferon and Growth Hormone." At one time Director of Genetic Engineering at Wadley Cancer Center and Assistant Professor, University of Texas Southwestern Medical School, Dallas.

Pioneer in Nantopes shown to be a highly effective treatment for Carcinoid cancers.

Licensed radiopharmaceutical manufacturer of diagnostic, therapeutic and aseptic drugs for terminal cancer patients. Three NDA approved products with four more in Phase 1,2 and 3. While at Union Carbide, produced quantities of radio chemicals and radio pharmaceuticals.

Evaluation of carbon nanotubes sheets as conductive substrates for cellular growth. Also focused on methods to direct nerve regeneration in the peripheral nervous system and spinal cord. Currently leads a team developing biosynthetic nerve prosthesis grafts for peripheral nerve gap repair. Also working towards fully functional bi-directional, sensory/motor peripheral neuro-electrical interfaces. Helped define the molecular mechanisms that guide development of nerve circuits in the spinal cord and possible genetic cause of rare human condition, congenital mirror movement disorder. Also assistant Professor of Neurology and Biomedical Engineering at the University of Texas Southwestern Medical Center, in Dallas.

This detection platform provides healthcare providers quick access to critical diagnostic and monitoring information. In respiratory gas detection applications, it reaches those currently underserved by traditional patient monitoring and offers significant advantages over existing solutions. It also simplifies and expands the use of biomolecule analysis, with potential applications in DNA, protein, and glucose detection, through easy-to-use Point-of-Care product configurations.

Co-founder of this bio-pharmaceutical startup devoted to treatment of viral diseases. Trained as a chemist; attended medical school and has practiced medicine for over thirty years. Holder of 8 issued patents. Served as a medical officer in the U.S. Army during the Vietnam era.

Research interests focused on developing radionuclear methods of analysis and its application to fundamental areas including Alzheimer disease, nanoscience and potential health impacts of fine airborne particulate. Many published research articles in U.S. and Canada. Expert in analytical chemistry.

Many published papers in the field of nanotechnology, biophysics , chemical carcinogensis and biomaterials. Extensive studies on soluble and membrane proteins in oxidative and glycerol metabolism pathways.

Biophysicist, BA and PhD at Technion Hafia, Postdoc at Weizmann institute of Science and at California Institute of Technology. Involved in the development of single molecule DNA sequencing while at Caltech. Consulted to Helicos Biosciences which form to develop and commercialize the innovative sequencing platform. Expert in antifreeze proteins and pioneer in the development of fluorescence techniques and microfluidics devices to investigate them. Member of NQPI - Nanoscale & Quantum Phenomena Institute and of QBI – Quantitative Biology Institute.

Currently focused to explore quantum-level interactions to study dynamics of biophysical and biochemical processes at the molecular level. Pioneer in the use of multi-photon excitation and light quenching in time-resolved fluorescence spectroscopy, as well as fluorescence sensing methods for biomedical applications in tissue and blood. Interests expanded to nanotechnology and applications of plasmonic effects induced by light in metallic nanostructures.

Research has involved the structure/function and metabolism of plasma lipoproteins, key components of cholesterol transport. Since 1998, research has been focused on using synthetic lipoproteins as drug carriers, particularly for cancer chemotherapy. Has published over 100 articles and has given numerous presentations at international meetings and Academic institutions around the world. Has organized four international meetings on high density lipoproteins and reverse cholesterol transport.

Bioengineer specializing in drug delivery from polymeric nanoparticles and bioconjugate chemistry. Currently focusing on the develppment of nano-therapeutics for various diseases such as cancer, glaucoma and COPD.

Nanotechnology research focusses on developing thermal ablative technologies for the treatment of urologic disease.

Chief Urologic Resident in Department of Urology at UTSW Medical Center Recipient of fellowships from the American Federation for Aging Research and the Cornell Molecular Biology department. Undergraduate degree, University of Pennsylvania; Medical degree, Weill Cornell Medical College.